Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Assunta De Rienzo, Ph.D.

Co-Author

This page shows the publications co-authored by Assunta De Rienzo and Raphael Bueno.
Connection Strength

5.789
  1. Association of RERG Expression with Female Survival Advantage in Malignant Pleural Mesothelioma. Cancers (Basel). 2021 Feb 02; 13(3).
    View in: PubMed
    Score: 0.943
  2. Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues. J Mol Diagn. 2017 01; 19(1):65-71.
    View in: PubMed
    Score: 0.704
  3. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res. 2016 Jan 15; 76(2):319-28.
    View in: PubMed
    Score: 0.656
  4. Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies. J Mol Diagn. 2014 Mar; 16(2):267-72.
    View in: PubMed
    Score: 0.578
  5. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res. 2013 May 01; 19(9):2493-502.
    View in: PubMed
    Score: 0.546
  6. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2011 Jan 15; 17(2):310-6.
    View in: PubMed
    Score: 0.465
  7. Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma. J Thorac Oncol. 2021 11; 16(11):1925-1935.
    View in: PubMed
    Score: 0.243
  8. Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma. Front Oncol. 2021; 11:684025.
    View in: PubMed
    Score: 0.242
  9. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J Pathol. 2021 01; 253(1):68-79.
    View in: PubMed
    Score: 0.231
  10. The Molecular Basis of Malignant Pleural Mesothelioma. Thorac Surg Clin. 2020 Nov; 30(4):383-393.
    View in: PubMed
    Score: 0.230
  11. Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas. J Thorac Cardiovasc Surg. 2020 10; 160(4):1078-1083.e2.
    View in: PubMed
    Score: 0.225
  12. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016 Apr; 48(4):407-16.
    View in: PubMed
    Score: 0.168
  13. Second generation sequencing of the mesothelioma tumor genome. PLoS One. 2010 May 13; 5(5):e10612.
    View in: PubMed
    Score: 0.112
  14. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing. BMC Med Genet. 2009 Dec 31; 10:149.
    View in: PubMed
    Score: 0.109
  15. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3521-6.
    View in: PubMed
    Score: 0.096
  16. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Commun Biol. 2021 04 14; 4(1):370.
    View in: PubMed
    Score: 0.060
  17. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma. J Thorac Oncol. 2021 01; 16(1):89-103.
    View in: PubMed
    Score: 0.057
  18. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. Immunity. 2019 05 21; 50(5):1317-1334.e10.
    View in: PubMed
    Score: 0.052
  19. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. Clin Cancer Res. 2016 Mar 01; 22(5):1197-210.
    View in: PubMed
    Score: 0.041
  20. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2012 Jan 01; 18(1):77-90.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.